Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308869 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Emmanuel L Luwaya und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Viral Load. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association-American Stroke Association, FIC NIH HHS, Fogarty International Center.
Abstract (Originalsprache)
Background
An increase in the prevalence of HIV drug resistance (HIVDR) has been reported in recent years, especially in persons on non-nucleoside reverse transcriptase inhibitors (NNRTIs) due to their low genetic barrier to mutations. However, there is a paucity of epidemiological data quantifying HIVDR in the era of new drugs like dolutegravir (DTG) in sub-Saharan Africa. We, therefore, sought to determine the prevalence and correlates of viral load (VL) suppression in adult people with HIV (PWH) on a fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) or tenofovir alafenamide/emtricitabine/dolutegravir (TAFED) and describe patterns of mutations in individuals failing treatment.
Methods
We conducted a cross-sectional study among 384 adults living with HIV aged ≥15 years between 5 th June 2023 and 10 th August 2023. Demographic, laboratory and clinical data were collected from electronic health records using a data collection form. Viral load suppression was defined as plasma HIV-1 RNA VL of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
ORCID-Profile: Emmanuel L Luwaya, Kaole Bwalya
Förderung
- American Heart Association-American Stroke Association
- FIC NIH HHS
- Fogarty International Center
- National Institute of Diabetes and Digestive and Kidney Diseases
- American Heart Association
Zitieren
APA
Luwaya, E. L., Mwape, L., Bwalya, K., Siakabanze, C., Hamooya, B. M., & Masenga, S. K. (2024). Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia. PLOS ONE. https://doi.org/10.1371/journal.pone.0308869
Vancouver
Luwaya EL, Mwape L, Bwalya K, Siakabanze C, Hamooya BM, Masenga SK. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia. PLOS ONE. 2024. doi:10.1371/journal.pone.0308869
BibTeX
@article{Luwaya2024,
author = {Luwaya, Emmanuel L and Mwape, Lackson and Bwalya, Kaole and Siakabanze, Chileleko and Hamooya, Benson M and Masenga, Sepiso K},
title = {Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308869}
}
EUVIMED